단국대학교 산학협력단;INDUSTRY-ACADEMIC COOPERATION FOUNDATION, DANKOOKUNIVERSITY;INDUSTRY-ACADEMIC COOPERATION FOUNDATION; DANKOOK UNIVERSITY
发明人:
LEE, SEONG WOOK,이성욱,YANG, BIT NA,양빛나,KIM, SUNG JIN,김성진,HAN, SEUNG RYUL,한승렬,LEE, SEONG WOOKKR,YANG, BIT NAKR,KIM, SUNG JINKR,HAN, SEUNG RYULKR
申请号：
KR1020160012804
公开号：
KR1020160095635A
申请日:
2016.02.02
申请国别(地区):
KR
年份:
2016
代理人:
摘要：
The present invention relates to a recombinant vector comprising a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) targeting trans-splicing ribozyme expression cassette for delivering a chimeric antigen receptor including (i) a trans-splicing ribozyme for targeting CTLA-4 and (ii) a polynucleotide for encoding a chimeric antigen receptor connected with a 3 exon of the ribozyme. Moreover, the present invention relates to a transformed cell in which the recombinant vector is introduced, a ribozyme expressed from the recombinant vector, a retrovirus for expressing the ribozyme, and a T cell treated by the retrovirus. Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition comprises the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof； and to a method for treating cancer, wherein the method comprises a step of administrating the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof into an entity requiring cancer treatment. The recombinant vector and the ribozyme expressed therefrom according to the present invention control CTLA-4 of a T cell, which has disturbed conventional anticancer treatment. At the same time, the recombinant vector and the ribozyme expressed therefrom make anticancer treatment possible. Accordingly, toxicity affecting normal cell is reduced through a gene cell therapy by which a more effective anticancer effect can be expected, so a treating effect and stability are improved. Thus, the recombinant vector and the ribozyme expressed therefrom can be widely utilized in the field of gene treatment in the future.본 발명은 (i) CTLA-4(Cytotoxic T-Lymphocyte-Associated Protein-4)를 표적으로 하는 트랜스-스플라이싱 라이보자임； (ii) 상기 라이보자임의 3' 엑손에 연결된 키메릭 항원 수용체(Chimeric antigen receptor)를 암호화하는 폴리뉴클레오티드를 포함하는, 키메릭 항원 수용체 전달용 CTLA-4 타겟팅 트랜스-스플라이싱 라이보자임 발현 카세트를 포함하는 것을 특
